中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
3期
54-56
,共3页
宫颈上皮内瘤变%宫颈癌组氨酸三联体%凋亡抑制蛋白%免疫组织化学%早期诊断
宮頸上皮內瘤變%宮頸癌組氨痠三聯體%凋亡抑製蛋白%免疫組織化學%早期診斷
궁경상피내류변%궁경암조안산삼련체%조망억제단백%면역조직화학%조기진단
Cervical intraepithelial neoplasia (CIN)Cervical carcinoma%Fragile histidine triad (FHIT)%Survivin%Immunohistochemistry%Early diagnosis
目的 研究脆性组氨酸三联体基因(FHIT)蛋白和凋亡抑制蛋白(survivin)在正常宫颈、宫颈上皮内瘤变和宫颈癌中的表达情况,探讨两者在宫颈癌早期诊断和发生发展中的临床意义.方法 采用免疫组织化学SP法检测20例正常宫颈组织;20例宫颈CIN Ⅰ级、25例CINⅡ/Ⅲ级;60例宫颈癌组织中的FHTT蛋白和凋亡抑制蛋白的表达.结果 FHIT蛋白在正常宫颈组、宫颈CIN组、CIN Ⅰ组、CINⅡ/Ⅲ组和宫颈癌组中的阴性率分别为0%(0/20)、24.4%(11/45)、10.0%(2/20)、36.0%(9/25)和66.7%(40/60),各组间阴性率比较差异有统计学意义(P＜0.05);凋亡抑制蛋白在正常宫颈组织、宫颈CIN组、宫颈癌组中的阳性率分别是20.0%(4/20)、31.1%(14/45)和95.0%(57/60),各组间阳性率比较差异有统计学意义(P＜0.05);在宫颈CIN和宫颈癌中,FHIT和凋亡抑制蛋白的表达有一定的相关性(P＜0.05).结论 检测宫颈CIN中的FHIT蛋白表达情况,可用作高级别的CIN筛查或预测.FHIT和凋亡抑制蛋白对于宫颈癌前期病变和宫颈癌的筛查和早期诊断具有一定的临床参考价值.
目的 研究脆性組氨痠三聯體基因(FHIT)蛋白和凋亡抑製蛋白(survivin)在正常宮頸、宮頸上皮內瘤變和宮頸癌中的錶達情況,探討兩者在宮頸癌早期診斷和髮生髮展中的臨床意義.方法 採用免疫組織化學SP法檢測20例正常宮頸組織;20例宮頸CIN Ⅰ級、25例CINⅡ/Ⅲ級;60例宮頸癌組織中的FHTT蛋白和凋亡抑製蛋白的錶達.結果 FHIT蛋白在正常宮頸組、宮頸CIN組、CIN Ⅰ組、CINⅡ/Ⅲ組和宮頸癌組中的陰性率分彆為0%(0/20)、24.4%(11/45)、10.0%(2/20)、36.0%(9/25)和66.7%(40/60),各組間陰性率比較差異有統計學意義(P＜0.05);凋亡抑製蛋白在正常宮頸組織、宮頸CIN組、宮頸癌組中的暘性率分彆是20.0%(4/20)、31.1%(14/45)和95.0%(57/60),各組間暘性率比較差異有統計學意義(P＜0.05);在宮頸CIN和宮頸癌中,FHIT和凋亡抑製蛋白的錶達有一定的相關性(P＜0.05).結論 檢測宮頸CIN中的FHIT蛋白錶達情況,可用作高級彆的CIN篩查或預測.FHIT和凋亡抑製蛋白對于宮頸癌前期病變和宮頸癌的篩查和早期診斷具有一定的臨床參攷價值.
목적 연구취성조안산삼련체기인(FHIT)단백화조망억제단백(survivin)재정상궁경、궁경상피내류변화궁경암중적표체정황,탐토량자재궁경암조기진단화발생발전중적림상의의.방법 채용면역조직화학SP법검측20례정상궁경조직;20례궁경CIN Ⅰ급、25례CINⅡ/Ⅲ급;60례궁경암조직중적FHTT단백화조망억제단백적표체.결과 FHIT단백재정상궁경조、궁경CIN조、CIN Ⅰ조、CINⅡ/Ⅲ조화궁경암조중적음성솔분별위0%(0/20)、24.4%(11/45)、10.0%(2/20)、36.0%(9/25)화66.7%(40/60),각조간음성솔비교차이유통계학의의(P＜0.05);조망억제단백재정상궁경조직、궁경CIN조、궁경암조중적양성솔분별시20.0%(4/20)、31.1%(14/45)화95.0%(57/60),각조간양성솔비교차이유통계학의의(P＜0.05);재궁경CIN화궁경암중,FHIT화조망억제단백적표체유일정적상관성(P＜0.05).결론 검측궁경CIN중적FHIT단백표체정황,가용작고급별적CIN사사혹예측.FHIT화조망억제단백대우궁경암전기병변화궁경암적사사화조기진단구유일정적림상삼고개치.
Objective To study the expression of fragile histidine triad (FHIT)and.survivin in normal cervix, cervical intraepithelial neoplasia(CIN) and cervical cancer. To discuss the potential involvement of FHIT and survivin in tumorigenesis, metastasis in cervical cancer; to discuss the significance of FHIT and survivin in early diagnosis of cervical cancer. Methods The expressions of FHIT protein and survivin were detected by immunohistochemistry in 20 cases of normal cervix, 20 cases of CIN Ⅰ ,25 cases of CIN Ⅱ/Ⅲ ,60 cases of cervical cancer. Results The percentages of negative expression of FHIT protein in normal tissues were 0% (0/20),24.4% ( 11/45 ) in CIN group, 10.0% (2/20) in CIN Ⅰ group, 36.0% ( 9/25 ) in CIN Ⅱ / Ⅲ group and 66.7%(40/60) in cervical cancer group. There were significant differences between groups (Chi-square test, P ＜0.05 ). The positive expression rate of survivin wase 20.0% ( 4/20 ) in normal group, 31.1% ( 14/45 ) in CIN group,and 95.0% (57/60)in cervical cancer group. There was significant difference between groups (Chisquare test, P ＜ 0.05 ). FHIT protein expression and survivin expression were negatively related ( P＜ 0.05 ) in CIN and cervical cancer. Conclusion Since the expression level of FHIT is associated with the grade of CIN, it can be used to screen or forecasting higher-grade-group of CIN. FHIT and survivin has clinical reference value for screening and early diagnosis of cervical lesions and cervical cancer.
